Stockreport

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range [Yahoo! Finance]

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
PDF –ORLADEYO net revenue expected to be between $625 million and $645 million in 2026– –BioCryst expects continued non-GAAP profitability in 2026 even after expected clo [Read more]